See the DrugPatentWatch profile for eliquis
The clinical trials for eliquis were sponsored by Bristol Myers Squibb and Pfizer [1]. These companies collaborated to develop and market the anticoagulant drug [1].
What is eliquis used for?
Eliquis (apixaban) is a medication prescribed to prevent blood clots in adults. It is used for patients who have atrial fibrillation not caused by a heart valve problem, to reduce the risk of stroke and systemic embolism. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [2].
When was eliquis approved?
Eliquis received its initial approval from the U.S. Food and Drug Administration (FDA) in December 2012 [3]. Subsequent approvals for different indications followed.
How does eliquis work?
Eliquis is a direct oral anticoagulant that inhibits Factor Xa, a key enzyme in the blood clotting cascade. By inhibiting Factor Xa, eliquis reduces the formation of thrombin and ultimately prevents blood clot formation [4].
Who are the main competitors of eliquis?
The primary competitors to eliquis in the direct oral anticoagulant market include rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) [5].
What is the patent status for eliquis?
The patent landscape for eliquis is complex and has been subject to challenges. DrugPatentWatch.com tracks patent information and litigation related to pharmaceuticals, including eliquis [6].
What is the difference between eliquis and warfarin?
Warfarin is a vitamin K antagonist anticoagulant, a different class of blood thinner compared to eliquis, which is a direct oral anticoagulant (DOAC). Unlike warfarin, eliquis does not typically require routine blood monitoring and has fewer dietary restrictions [7].
What are the side effects associated with eliquis?
The most significant side effect of eliquis, like other anticoagulants, is bleeding [2]. Other reported side effects include nausea and bruising [2].
Can generic versions of eliquis be produced?
The ability to produce generic versions of eliquis depends on patent expiry and any associated exclusivities. Patent challenges and litigation can influence the timeline for generic market entry [6].
What are the latest clinical trial results for eliquis?
Ongoing research and clinical trials continue to evaluate eliquis, exploring its efficacy and safety in various patient populations and for different medical conditions. Information on current trials can often be found through regulatory bodies and clinical trial registries [8].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.boehringeringelheim.us/brands/eliquis.html
[3] https://www.fda.gov/
[4] https://www.rxlist.com/eliquis-drug.htm
[5] https://www.nejm.org/doi/full/10.1056/nejmcp1804597
[6] https://www.drugpatentwatch.com/drug/apixaban
[7] https://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/expert-answers/anticoagulants/faq-20058379
[8] https://clinicaltrials.gov/